Shares of Capricor Therapeutics Inc. (CAPR) are down more than 40% from their 52-week high of $23.40, recorded last October, and trade around $13.
This biotechnology company is working on a new treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com